Discovery of a Potent and Selective Inhibitor of Cyclin-Dependent Kinase 4/6
The DOI matches its Crossref record; 50 of the 50 references it cites were found in a registry or an index.
Abstract
A pharmacological approach to inhibition of cyclin-dependent kinases 4 and 6 (Cdk4/6) using highly selective small molecule inhibitors has the potential to provide novel cancer therapies for clinical use. Achieving high levels of selectivity for Cdk4/6, versus other ATP-dependent kinases, presents a significant challenge. The pyrido[2,3-d]pyrimidin-7-one template provides an effective platform for the inhibition of a broad cross-section of kinases, including Cdks. It is now demonstrated that the modification of pyrido[2,3-d]pyrimidin-7-ones to include a 2-aminopyridine side chain at the C2-position provides inhibitors with exquisite selectivity for Cdk4/6 in vitro. This selectivity profile is recapitulated in cells where the most selective inhibitors create a G(1) block at concentrations up to 100-fold the IC(50) for cell proliferation. On the basis of its selectivity profile and pharmacokinetic profile, compound 43 (PD 0332991) was identified as a drug candidate for the treatment of cancer.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The text we found for this paper looks like another document, so the self-check wasn’t run.
Citations
Cites
1 retracted
Prevention of Chemotherapy-Induced Alopecia in Rats by CDK Inhibitors
Davis, S. T., Benson, B. G., Bramson, H. N., Chapman, D. E., Dickerson, S. H., Dold, K. M., Eberwein, D. J., Edelstein, M., Frye, S. V., Gampe, R. T., et al. (2001) · Science · doi:10.1126/science.291.5501.134 · Cited by 166
RetractedThe RB and p53 pathways in cancer
Sherr, C. J., & McCormick, F. (2002) · Cancer Cell · doi:10.1016/s1535-6108(02)00102-2 · Cited by 1,690
Synthesis of Macroporous Minerals with Highly Ordered Three-Dimensional Arrays of Spheroidal Voids
Holland, B. T., Blanford, C. F., & Stein, A. (1998) · Science · doi:10.1126/science.281.5376.538 · Cited by 1,484
To cycle or not to cycle: a critical decision in cancer
Malumbres, M., & Barbacid, M. (2001) · Nature Reviews Cancer · doi:10.1038/35106065 · Cited by 1,468
The specificities of protein kinase inhibitors: an update
BAIN, J., McLAUCHLAN, H., ELLIOTT, M., & COHEN, P. (2003) · Biochemical Journal · doi:10.1042/bj20021535 · Cited by 1,369
Meijer, L., Borgne, A., Mulner, O., Chong, J. P. J., Blow, J. J., Inagaki, N., Inagaki, M., Delcros, J., & Moulinoux, J. (1997) · European Journal of Biochemistry · doi:10.1111/j.1432-1033.1997.t01-2-00527.x · Cited by 1,352
Hoessel, R., Leclerc, S., Endicott, J. A., Nobel, M. E. M., Lawrie, A., Tunnah, P., Leost, M., Damiens, E., Marie, D., Marko, D., et al. (1999) · Nature Cell Biology · doi:10.1038/9035 · Cited by 809
Cyclin-dependent kinase 2 is essential for meiosis but not for mitotic cell division in mice
Ortega, S., Prieto, I., Odajima, J., Martín, A., Dubus, P., Sotillo, R., Barbero, J. L., Malumbres, M., & Barbacid, M. (2003) · Nature Genetics · doi:10.1038/ng1232 · Cited by 796
Inhibition of Cyclin‐Dependent Kinases by Purine Analogues
Veselý, J., Havliček, L., Strnad, M., Blow, J. J., Donella‐Deana, A., Pinna, L., Letham, D. S., Kato, J., Detivaud, L., Leclerc, S., et al. (1994) · European Journal of Biochemistry · doi:10.1111/j.1432-1033.1994.00771.x · Cited by 632
Anticancer drug targets: cell cycle and checkpoint control
Shapiro, G. I., & Harper, J. W. (1999) · Journal of Clinical Investigation · doi:10.1172/jci9054 · Cited by 464
Meijer, L., Thunnissen, A.-M., White, A., Garnier, M., Nikolic, M., Tsai, L.-H., Walter, J., Cleverley, K., Salinas, P., Wu, Y.-Z., et al. (2000) · Chemistry & Biology · doi:10.1016/s1074-5521(00)00063-6 · Cited by 454
McClue, S. J., Blake, D., Clarke, R., Cowan, A., Cummings, L., Fischer, P. M., MacKenzie, M., Melville, J., Stewart, K., Wang, S., et al. (2002) · International Journal of Cancer · doi:10.1002/ijc.10738 · Cited by 364
Schultz, C., Link, A., Leost, M., Zaharevitz, D. W., Gussio, R., Sausville, E. A., Meijer, L., & Kunick, C. (1999) · Journal of Medicinal Chemistry · doi:10.1021/jm9900570 · Cited by 334
Cyclin-Dependent Kinase Inhibitors: Useful Targets in Cell Cycle Regulation
Sielecki, T. M., Boylan, J. F., Benfield, P. A., & Trainor, G. L. (2000) · Journal of Medicinal Chemistry · doi:10.1021/jm990256j · Cited by 323
Human Myt1 Is a Cell Cycle-regulated Kinase That Inhibits Cdc2 but Not Cdk2 Activity
Booher, R. N., Holman, P. S., & Fattaey, A. (1997) · Journal of Biological Chemistry · doi:10.1074/jbc.272.35.22300 · Cited by 313
Bramson, H. N., Corona, J., Davis, S. T., Dickerson, S. H., Edelstein, M., Frye, S. V., Gampe, R. T., Harris, P. A., Hassell, A., Holmes, W. D., et al. (2001) · Journal of Medicinal Chemistry · doi:10.1021/jm010117d · Cited by 269
Role of the retinoblastoma protein in the pathogenesis of human cancer.
Sellers, W. R., & Kaelin, W. G. (1997) · Journal of Clinical Oncology · doi:10.1200/jco.1997.15.11.3301 · Cited by 253
Havlíček, L., Hanuš, J., Veselý, J., Leclerc, S., Meijer, L., Shaw, G., & Strnad, M. (1997) · Journal of Medicinal Chemistry · doi:10.1021/jm960666x · Cited by 243
Structure-based design of a potent purine-based cyclin-dependent kinase inhibitor
Davies, T. G., Bentley, J., Arris, C. E., Boyle, F. T., Curtin, N. J., Endicott, J. A., Gibson, A. E., Golding, B. T., Griffin, R. J., Hardcastle, I. R., et al. (2002) · Nature Structural Biology · doi:10.1038/nsb842 · Cited by 219
Small Molecules as Inhibitors of Cyclin‐Dependent Kinases
Huwe, A., Mazitschek, R., & Giannis, A. (2003) · Angewandte Chemie International Edition · doi:10.1002/anie.200200540 · Cited by 181
Inhibition of Cyclin-Dependent Kinase 4 (Cdk4) by Fascaplysin, a Marine Natural Product
Soni, R., Muller, L., Furet, P., Schoepfer, J., Stephan, C., Zumstein-Mecker, S., Fretz, H., & Chaudhuri, B. (2000) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.2000.3349 · Cited by 166
CDK inhibition and cancer therapy
Garrett, M. D., & Fattaey, A. (1999) · Current Opinion in Genetics & Development · doi:10.1016/s0959-437x(99)80015-x · Cited by 163
Complexities in the development of cyclin-dependent kinase inhibitor drugs
Sausville, E. A. (2002) · Trends in Molecular Medicine · doi:10.1016/s1471-4914(02)02308-0 · Cited by 160
CVT-313, a Specific and Potent Inhibitor of CDK2 That Prevents Neointimal Proliferation
Brooks, E. E., Gray, N. S., Joly, A. H., Kerwar, S. S., Lum, R. T., Mackman, R. L., Norman, T., Rosete, J., Rowe, M. W., Schow, S. R., et al. (1997) · Journal of Biological Chemistry · doi:10.1074/jbc.272.46.29207 · Cited by 160
Pyrido[2,3-d]pyrimidin-7-one Inhibitors of Cyclin-Dependent Kinases
Barvian, M., Boschelli, D. H., Cossrow, J., Dobrusin, E., Fattaey, A., Fritsch, A., Fry, D., Harvey, P., Keller, P., Garrett, M., et al. (2000) · Journal of Medicinal Chemistry · doi:10.1021/jm000271k · Cited by 155
Self-citationMettey, Y., Gompel, M., Thomas, V., Garnier, M., Leost, M., Ceballos-Picot, I., Noble, M., Endicott, J., Vierfond, J.-M., & Meijer, L. (2003) · Journal of Medicinal Chemistry · doi:10.1021/jm020319p · Cited by 146
Senderowicz, A. M. (2002) · The Oncologist · doi:10.1634/theoncologist.7-suppl_3-12 · Cited by 129
Pyrido[2,3- d ]pyrimidin-7-ones as Specific Inhibitors of Cyclin-Dependent Kinase 4
VanderWel, S. N., Harvey, P. J., McNamara, D. J., Repine, J. T., Keller, P. R., Quin, J., Booth, R. J., Elliott, W. L., Dobrusin, E. M., Fry, D. W., et al. (2005) · Journal of Medicinal Chemistry · doi:10.1021/jm049355+ · Cited by 119
Self-citationAnderson, M., Beattie, J. F., Breault, G. A., Breed, J., Byth, K., Culshaw, J. D., Ellston, R. P. A., Green, S. A., Minshull, C. A., Norman, R. A., et al. (2003) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/s0960-894x(03)00638-3 · Cited by 113
Selective In Vivo and In Vitro Effects of a Small Molecule Inhibitor of Cyclin-Dependent Kinase 4
Soni, R., O'Reilly, T., Furet, P., Muller, L., Stephan, C., Zumstein-Mecker, S., Fretz, H., Fabbro, D., & Chaudhuri, B. (2001) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/93.6.436 · Cited by 97
Cyclin‐dependent kinase inhibitors for treating cancer
Toogood, P. L. (2001) · Medicinal Research Reviews · doi:10.1002/med.1021 · Cited by 94
Self-citationLegraverend, M., Tunnah, P., Noble, M., Ducrot, P., Ludwig, O., Grierson, D. S., Leost, M., Meijer, L., & Endicott, J. (2000) · Journal of Medicinal Chemistry · doi:10.1021/jm9911130 · Cited by 90
Beattie, J. F., Breault, G. A., Ellston, R. P. A., Green, S. A., Jewsbury, P. J., Midgley, C. J., Naven, R. T., Minshull, C. A., Pauptit, R. A., Tucker, J. A., et al. (2003) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/s0960-894x(03)00202-6 · Cited by 88
2-Substituted paullones: CDK1/cyclin B-inhibiting property and in vitro antiproliferative activity
Kunick, C., Schultz, C., Lemcke, T., Zaharevitz, D. W., Gussio, R., Jalluri, R. K., Sausville, E. A., Leost, M., & Meijer, L. (2000) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/s0960-894x(00)00048-2 · Cited by 86
Cyclin-dependent kinase inhibitors: novel anticancer agents
Mani, S., Wang, C., Wu, K., Francis, R., & Pestell, R. G. (2000) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.9.8.1849 · Cited by 86
2,6,9-trisubstituted purines : Optimization towards highly potent and selective CDK1 inhibitors
Imbach, P. A., Capraro, H., Furet, P., Mett, H., Meyer, T., & Zimmermann, J. (1999) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/s0960-894x(98)00691-x · Cited by 83
Indenopyrazoles as Novel Cyclin Dependent Kinase (CDK) Inhibitors
Nugiel, D. A., Etzkorn, A.-M., Vidwans, A., Benfield, P. A., Boisclair, M. D., Burton, C. R., Cox, S. E., Czerniak, P. M., Doleniak, D., & Seitz, S. P. (2001) · Journal of Medicinal Chemistry · doi:10.1021/jm0100032 · Cited by 80
Nugiel, D. A., Vidwans, A., Etzkorn, A.-M., Rossi, K. A., Benfield, P. A., Burton, C. R., Cox, S. E., Doleniak, D., & Seitz, S. P. (2002) · Journal of Medicinal Chemistry · doi:10.1021/jm020171+ · Cited by 78
Sayle, K. L., Bentley, J., Boyle, F. T., Calvert, H., Cheng, Y., Curtin, N. J., Endicott, J., Golding, B. T., Hardcastle, I. R., Jewsbury, P. J., et al. (2003) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/s0960-894x(03)00651-6 · Cited by 70
Breault, G. A., Ellston, R. P. A., Green, S. A., James, S., Jewsbury, P. J., Midgley, C. J., Pauptit, R. A., Minshull, C. A., Tucker, J. A., & Pease, J. E. (2003) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/s0960-894x(03)00203-8 · Cited by 63
Novel, potent and selective cyclin D1/CDK4 inhibitors: indolo[6,7-a]pyrrolo[3,4-c]carbazoles
Engler, T. A., Furness, K., Malhotra, S., Sánchez-Martínez, C., Shih, C., Xie, W., Zhu, G., Zhou, X., Conner, S. E., Faul, M. M., et al. (2003) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/s0960-894x(03)00461-x · Cited by 62
Dreyer, M., Borcherding, D. R., Dumont, J. A., Peet, N. P., Tsay, J. T., Wright, P. S., Bitonti, A. J., Shen, J., & Kim, S. (2000) · Journal of Medicinal Chemistry · doi:10.1021/jm001043t · Cited by 61
4-Alkoxy-2,6-diaminopyrimidine derivatives: inhibitors of cyclin dependent kinases 1 and 2
Mesguiche, V., Parsons, R. J., Arris, C. E., Bentley, J., Boyle, F. T., Curtin, N. J., Davies, T. G., Endicott, J., Gibson, A. E., Golding, B. T., et al. (2003) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/s0960-894x(02)00884-3 · Cited by 56
Structure–activity relationship studies of flavopiridol analogues
Murthi, K. K., Dubay, M., McClure, C., Brizuela, L., Boisclair, M. D., Worland, P. J., Mansuri, M. M., & Pal, K. (2000) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/s0960-894x(00)00156-6 · Cited by 55
Identification of selective inhibitors of cyclin dependent kinase 4
Carini, D. J., Kaltenbach, R. F. I., Liu, J., Benfield, P. A., Boylan, J. F., Boisclair, M. D., Brizuela, L., Burton, C. R., Cox, S. E., Grafström, R. H., et al. (2001) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/s0960-894x(01)00416-4 · Cited by 49
Pyrazolo[3,4-b]quinoxalines. A new class of cyclin-Dependent kinases inhibitors
Ortega, M. A., Romero-Montoya, M. E., Zarranz, B., Jaso, A., Aldana, I., Leclerc, S., Meijer, L., & Monge, A. (2002) · Bioorganic & Medicinal Chemistry · doi:10.1016/s0968-0896(02)00069-x · Cited by 44
Targeting hyperproliferative disorders with cyclin dependent kinase inhibitors
Rosania, G. R., & Chang, Y. (2000) · Expert Opinion on Therapeutic Patents · doi:10.1517/13543776.10.2.215 · Cited by 43
Alterations in G1/S Cell‐Cycle Control Contributing to Carcinogenesis
Kaelin, W. G. (1997) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.1997.tb48589.x · Cited by 35
Novel drugs targeting the cell cycle
Webster, K. R., & Kimball, S. D. (2000) · Emerging Drugs · doi:10.1517/14728214.5.1.45 · Cited by 33
Furet, P., Meyer, T., Mittl, P. R. E., & Fretz, H. (2001) · Journal of Computer-Aided Molecular Design · doi:10.1023/a:1011128510728 · Cited by 12
Research works printed but not linked: 46
- Fisher P. M., 2003, Expert. Opin. Investig. Drugs, 12, 970
- Fisher P. M, 2001, Curr. Opin. Drug Discuss. Dev., 4, 634
- Fry D. W., 2000, Curr. Opin. Oncol., Endocrine Metab. Invest. Drugs, 2, 59
- Gray N., 1999, Curr. Med. Chem., 6, 875
- Fry D. W., 2001, J. Biol. Chem., 276, 16623
- Wang S., 2001, Synthesis and configuration of the cyclin-dependent kinase inhibitor roscovitine and its enantiomer. Tetrahedron: Asymmetry
- Chang Y.-T., 1999, Chem. Biol., 6, 375
- Schow S. R., 1997, Bioorg. Med. Chem. Lett., 7, 2702
- Zaharevitz D. W., 1999, Cancer Res., 59, 2569
- Gussio R., 2000, Anti-Cancer Drug Des., 15, 66
- Kunick C., 2000, Bioorg. Med. Chem. Lett., 10, 569, 10.1016/S0960-894X(00)00048-2 · DOI
- Tang J., 2003, Bioorg. Med. Chem. Lett., 13, 2988
- Misra R. N., 2003, Bioorg. Med. Chem. Lett., 13, 2408
- Misra R. N., 2003, Bioorg. Med. Chem. Lett., 13, 1136
- Song Y., 2002, Bioorg. Med. Chem. Lett., 12, 1132
- Kim K. S., 2002, J. Med. Chem., 45, 3927
- Furet P., 2002, Bioorg. Med. Chem. Lett., 12, 224
- Sielecki T. M., 2001, Bioorg. Med. Chem. Lett., 11, 1160
- Sasaki S., 1998, Bioorg. Med. Chem. Lett., 8, 1022
- Seong Y.-S., 2003, Cancer Res., 63, 7391
- Kim K. S., 2000, J. Med Chem., 43, 4134
- Li X., 2003, Bioorg. Med. Chem. Lett., 13, 1942
- Liu J.-J., 2003, Bioorg. Med. Chem. Lett., 13, 2468
- Yue E. W., 2002, J. Med. Chem., 45, 5248
- Lane M. E., 2001, Cancer Res., 61, 6177
- Andreani A., 2000, Anti-Cancer Drug Des., 15, 452
- Sanchez-Martinez C., 2003, Bioorg. Med. Chem. Lett., 13, 3839
- Sanchez-Martinez C., 2003, Bioorg. Med. Chem. Lett., 13, 3846
- Zhu G., 2003, Bioorg. Med. Chem. Lett., 13, 1235
- Ryu C.-K., 2000, Bioorg. Med. Chem. Lett., 10, 464
- Honma T., 2001, J. Med. Chem., 44, 4627
- Honma T., 2001, J. Med. Chem., 44, 4640
- Jeong H.-W., 2000, Bioorg. Med. Chem. Lett., 10, 1822
- Zhu G., 2003, J. Med. Chem., 46, 2030
- Bartek J., 2003, Biochem. J., 371, 204
- Bartkova J., 1997, Prog. Cell Cycle Res., 3, 220
- Hall M., 1996, Adv. Cancer Res., 68, 108
- Misra R. N., 2004, Chem
- Kelland L. R., 2000, Exp. Opin. Invest. Drugs, 9, 2911
- Chao S.-H., 2001, J. Biol. Chem., 276, 31799
- Chao S.-H., 2000, J. Biol. Chem., 275, 28348
- Tetsu O., 2003, Cancer Cell, 2, 245
- Fry D. W., 2004, Mol. Cancer Ther., 3, 1437
- Meyerson M., 1994, Mol. Cell Biol., 14, 2086
- Fry D. W., 1994, Anticancer Drug Des., 9, 351
- Fry D. W., 1997, Biochem. Pharmacol., 54, 887
Cited by
Epidermal Growth Factor Receptor Cell Proliferation Signaling Pathways
Wee, P., & Wang, Z. (2017) · Cancers · doi:10.3390/cancers9050052 · Cited by 2,027
Cristofanilli, M., Turner, N. C., Bondarenko, I., Ro, J., Im, S.-A., Masuda, N., Colleoni, M., DeMichele, A., Loi, S., Verma, S., et al. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(15)00613-0 · Cited by 1,827
The history and future of targeting cyclin-dependent kinases in cancer therapy
Asghar, U., Witkiewicz, A. K., Turner, N. C., & Knudsen, E. S. (2015) · Nature Reviews Drug Discovery · doi:10.1038/nrd4504 · Cited by 1,767
Palbociclib in hormone-receptor-positive advanced breast cancer
Turner, N. C., Ro, J., André, F., Loi, S., Verma, S., Iwata, H., Harbeck, N., Loibl, S., Huang Bartlett, C., Zhang, K., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1505270 · Cited by 1,590
Finn, R. S., Dering, J., Conklin, D., Kalous, O., Cohen, D. J., Desai, A. J., Ginther, C., Atefi, M., Chen, I., Fowst, C., et al. (2009) · Breast Cancer Research · doi:10.1186/bcr2419 · Cited by 1,398
“PD 0332991 is an orally active potent and highly selective inhibitor of CDK4 and CDK6 kinases, which in low nanomolar concentrations blocks pRb phosphorylation - subsequently inducing G1 arrest in sensitive cell lines [26-29].”
Background
Metadata
- Authors
- Toogood, P. L., Harvey, P. J., Repine, J. T., Sheehan, D. J., VanderWel, S. N., Zhou, H., Keller, P. R., McNamara, D. J., Sherry, D., Zhu, T., Brodfuehrer, J., Choi, C., Barvian, M. R., & Fry, D. W.
- Affiliations
- Pfizer (United States) (US)
- Corresponding author
- Toogood, Peter L.
- Venue
- Journal of Medicinal Chemistry
- Publisher
- American Chemical Society (ACS)
- Published
- 2005-03-02
- Volume
- 48
- Issue
- 7
- Pages
- 2388-2406
- ISSN
- 0022-2623 (ISSN-L)
- 1520-4804
- OpenAlex
- W1985389450
- Cited by
- 513
- References
- 50
- Citations by year
- 2026: 23 · 2025: 41 · 2024: 20 · 2023: 25 · 2022: 38 · 2021: 32 · 2020: 32 · 2019: 30 · 2018: 44 · 2017: 42 · 2016: 34 · 2015: 17 · 2014: 21 · 2013: 21 · 2012: 17
- FWCI
- 7.78
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Journal of Medicinal Chemistry (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Physical Sciences › Chemistry › Organic Chemistry › Heterocyclic Compound Synthesis and Bioactivity
- Health Sciences › Medicine › Oncology › Advanced Breast Cancer Therapies
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › PI3K/AKT/mTOR signaling in cancer
- Keywords
- CDK4/6, CDK4/6 inhibitors, kinase selectivity, G1 cell cycle arrest, palbociclib, small-molecule kinase inhibitors, anticancer drug candidates, pharmacokinetics
- MeSH terms
- Animals, Antineoplastic Agents, Biological Availability, Humans, Male, Piperazines, Proto-Oncogene Proteins, Pyridines, Pyrimidines, Structure-Activity Relationship, Thymidine, G1 Phase, Rats, Sprague-Dawley, Cyclin-Dependent Kinases, Cell Line, Tumor, Cell Proliferation, Cyclin-Dependent Kinase 4, Cyclin-Dependent Kinase 6, Rats
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.